XCancer

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors

Description:

Many types of cancers overexpress a receptor for the vitamin folate (Folate Receptor). This Phase 2 study will utilize a standard imaging radionuclide, technetium-99m, conjugated to a ligand (EC20) designed to bind to the folate receptor. The study is designed as an open-label, baseline-controlled study.

Sponsor:

Endocyte

Phase:

Phase 2

Contacts:

Nelson Oyesiku, MD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT01689727 - Click here to see study on

ClinicalTrials.gov

EC20

Isotope(s):
Target(s):
  • FR (Folate Receptor)
Ligand Class: Small Molecules
Inclusion
  • Subject must have a pituitary tumor.
  • Subject must be 18 years of age or older.
  • Subjects must meet the following eligibility requirements to be enrolled in the study:
  • Subject must have good kidney function.3\. Subject must provide written informed consent prior to enrollment.
Exclusion
  • Subject is unable to tolerate conditions for radionuclide imaging.
  • Subject is simultaneously participating in another investigational drug study.
  • Subject has completed the follow-up phase of any previous study loess than 30 days prior to enrollment in this study.
  • Subjects must be excluded if any of the following conditions are present:
  • Subject is pregnant or breastfeeding.